Skip to content

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arena Pharmaceuticals to Host R&D Day on October 4 in New York City
SAN DIEGO , Sept. 21, 2018 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Company will host an R&D Day to outline key catalysts and new information on the clinical programs for its potentially first- or best-in-class late-stage investigational compounds:
View HTML
Toggle Summary Arena Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO , Sept. 20, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that members of its senior management team will participate in the upcoming investor conferences: Cantor Global Healthcare Conference – Presenting on Tuesday, October 2 , at 1:40 p.m.
View HTML
Toggle Summary Arena Pharmaceuticals Presents Preclinical Data for Olorinab at International Association for the Study of Pain World Congress
SAN DIEGO , Sept. 17, 2018 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that results from preclinical studies of its investigative drug candidate olorinab, a peripherally restricted, highly selective, full agonist of the cannabinoid receptor 2 (CB 2 ) in development
View HTML
Toggle Summary Arena Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO , Aug. 29, 2018 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that members of its senior management team will participate in the upcoming investor conferences: Wells Fargo Securities Global Healthcare Conference – Presenting on Wednesday, September 5 at 2:25
View HTML
Toggle Summary Arena Pharmaceuticals Presented Phase 1 Clinical Data for Ralinepag in Pulmonary Arterial Hypertension at the European Society of Cardiology
SAN DIEGO , Aug. 28, 2018 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that data from two Phase 1 clinical studies evaluating an extended-release (XR) formulation of its investigative drug candidate ralinepag, a next-generation, oral, selective and potent prostacyclin
View HTML
Toggle Summary Eisai Inc. Announces Positive Topline Results from CAMELLIA-TIMI61, a Large-Scale Cardiovascular Outcome Trial for the Anti-Obesity Agent BELVIQ
<p><strong>WOODCLIFF LAKE, N.J., JULY 17, 2018 – </strong>Eisai Inc. announced positive topline results from the <a href="https://clinicaltrials.gov/ct2/show/NCT02019264">CAMELLIA-TIMI 61</a> cardiovascular outcome trial. This 12,000 patient study of BELVIQ<strong><sup>®</sup></strong> (lorcaserin HCl) CIV 10 mg twice-daily was conducted at over 400 sites in eight countries including the United States in collaboration with the Thrombolysis in Myocardial Infarction (TIMI) Study Group and is the largest cardiovascular (CV) outcome trial to date for a weight loss medication.</p>
View HTML
Toggle Summary Arena Pharmaceuticals Appoints Life Sciences Industry Veteran Kieran T. Gallahue to Board of Directors
SAN DIEGO , July 10, 2018 /PRNewswire/ --&nbsp; Arena Pharmaceuticals, Inc. (Nasdaq: ARNA), a biopharmaceutical company focused on delivering novel, transformational medicines across multiple therapeutic areas, today announced the appointment of Kieran T. Gallahue as a non-executive director. Mr.
View HTML
Toggle Summary Arena Pharmaceuticals Announces Data Presentation for Ralinepag in Pulmonary Arterial Hypertension at the American Thoracic Society International Conference
SAN DIEGO , May 21, 2018 /PRNewswire/ --&nbsp; Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced&nbsp;that data from a post-hoc analysis of the 22-week Phase 2 clinical study for its investigative drug candidate ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist
View HTML
Toggle Summary Arena Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO , May 10, 2018 /PRNewswire/ --&nbsp; Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced&nbsp;that Amit D. Munshi , President and Chief Executive Officer, will present at the following investor conferences: Bank of America Merrill Lynch Healthcare Conference in Las Vegas, NV on Thursday, May
View HTML
Toggle Summary Arena Pharmaceuticals and Outpost Medicine Enter into Licensing Agreement for Undisclosed Novel Compound
- Arena's non-core, proprietary, preclinical compound provides strategic fit with Outpost Medicine's expertise in developing products for genitourinary disorders SAN DIEGO and INDIANAPOLIS , May 1, 2018 /PRNewswire/ --&nbsp; Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), a biopharmaceutical company focused
View HTML